Stay updated on ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Sign up to get notified when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    13 days ago
    Change Detected
    Summary
    A new site revision tag 'Revision: v3.4.2' was added, and the previous banner about government funding and the older revision 'v3.4.1' were removed.
    Difference
    0.4%
    Check dated 2026-02-11T14:19:39.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide notice about a lapse in government funding was added, and the page version updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-04T10:25:15.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The page now displays a glossary and includes new metadata sections (Last Update Submitted that Met QC Criteria and Last Update Posted), plus a No FEAR Act Data notice and Revision: v3.4.0. The previous items (Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), No FEAR Act data, and Revision: v3.3.4) are removed.
    Difference
    0.2%
    Check dated 2026-01-28T06:17:45.000Z thumbnail image
  5. Check
    42 days ago
    Change Detected
    Summary
    Revision: v3.3.4 added and Revision: v3.3.3 removed; this appears to be a backend release update with no visible changes to the study page.
    Difference
    0.0%
    Check dated 2026-01-14T02:58:23.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Added multiple site contact phone numbers and removed outdated numbers; updated Last Update Posted timestamps. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.7%
    Check dated 2026-01-07T00:57:45.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    A new Locations section lists recruitment sites in Illinois, Iowa, Maryland, Michigan, Minnesota, and Wisconsin, and the page revision is updated to v3.3.3. The HHS Vulnerability Disclosure link and older location entries were removed.
    Difference
    0.7%
    Check dated 2025-12-23T22:04:11.000Z thumbnail image

Stay in the know with updates to ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ADT and Pembrolizumab in AR-positive Salivary Gland Carcinoma Clinical Trial page.